Search clinical trials for: OMBRABULIN (AVE8062)

Total 27 results

Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

Solid Tumor

Japan
Sanofi

Completed

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Neoplasms

France, Italy, Switzerland
Sanofi

Completed

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Sarcoma

Belgium, Hungary, United States, Brazil, France, India, Italy, Serbia, Spain, United Kingdom
Sanofi

Completed

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Neoplasms, Malignant

Belgium
Sanofi

Completed

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

Non-small Cell Lung Cancer

France, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Advanced Neoplastic Disease
Sanofi

Completed

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Sanofi

Completed

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (OPSALIN)

Ovarian Cancer Recurrent

Belgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
Sanofi

Completed

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Neoplasms, Malignant

France, United Kingdom, Italy
Michael J. Fox Foundation for Parkinson's Research
Sanofi

Terminated

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Sanofi

Terminated

Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)

Hungary
Astellas Pharma Global Development, Inc.
National Institute on Drug Abuse (NIDA)

Completed

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder
Sanofi

Completed

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)

Cancer | Venous Thromboembolism

France, Spain, Hong Kong, Austria, Canada, Lithuania, South Africa, Sweden, Romania, United States, Greece, Korea, Republic of, Ukraine, Argentina, Australia, Belarus, Belgium, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czech... and more
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

Healthy Volunteers

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Fibromyalgia

United States
Sanofi

Terminated

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility (SAVE-VEMED)

Venous Thromboembolism

United States, France, Canada, Romania, Russian Federation, Ukraine, Germany, Italy, Netherlands, Spain, Estonia, India, Czech Republic, Mexico, Hungary, Lithuania, United Kingdom, Korea, Republic of, Australia, Austria, Latvia, New...
Sanofi

Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (SAVE-KNEE)

Venous Thromboembolism

United States, Canada, Poland, Romania, Russian Federation, Ukraine, Estonia, Czech Republic, Mexico, Argentina, Denmark, Lithuania, Colombia, Australia, Belarus, South Africa, Greece
Sanofi

Completed

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery (SAVE-HIP3)

Venous Thromboembolism

United States, Canada, Russian Federation, Ukraine, Turkey, India, Mexico, Egypt, Lithuania, Colombia, Peru, Korea, Republic of, Chile, Belarus, China, South Africa
Sanofi

Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery (SAVE-HIP2)

Venous Thromboembolism

United States, Canada, Poland, Romania, Russian Federation, Ukraine, Italy, Portugal, Spain, Sweden, Turkey, Bulgaria, India, Czech Republic, Mexico, Argentina, Denmark, Finland, Peru, Chile, Belarus, China, South Africa, Greece, Colombia
Sanofi

Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)

Venous Thromboembolism

United States, Canada, Poland, Romania, Russian Federation, Ukraine, Germany, Italy, Spain, Sweden, Turkey, Estonia, India, Philippines, Czech Republic, Mexico, Argentina, Denmark, Finland, Norway, Colombia, Peru, Slovakia, Australia, C... and more
National Institute on Alcohol Abuse and Alcoholism...
Astellas Pharma Inc

Completed

Human Laboratory Study of ASP8062 for Alcohol Use Disorder

Alcohol Drinking | Alcohol Use Disorder | Alcohol Use Disorder (AUD)

United States
Sanofi

Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery (SAVE-ABDO)

Venous Thromboembolism

Belgium, Australia, Denmark, Austria, Greece, Korea, Republic of, Peru, Sweden, Italy, Belarus, India, Romania, Serbia, Slovenia, Germany, Latvia, Lithuania, Ukraine, Russian Federation, Spain, Estonia, Poland, Croatia, South Africa, United... and more
Sanofi

Completed

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery (TREK)

Venous Thromboembolism

Poland, Romania, Russian Federation, Portugal, Sweden, Turkey, Bulgaria, Malaysia, Philippines, Taiwan, Mexico, Argentina, Denmark, Finland, Norway, Colombia, Chile, Thailand, Greece

Search clinical trials for: OMBRABULIN (AVE8062)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations